ArchiMed appoints three new operating and strategic partners
All are C-Suite healthcare executives who have successfully executed investment and growth strategies in diverse global regions.
November 19, 2019 – Christophe Berthoux, Jean-Yves Desmottes and Mario Philips are joining the leadership team of European private equity healthcare specialist ArchiMed. They bring strategic and operational insight, wide-ranging international experience and extensive industry networks to ArchiMed and its portfolio companies. The appointments highlight ArchiMed’s commitment to providing strategic and tactical advantages, in addition to financial muscle, to portfolio companies.
“These appointments reinforce our positioning as a value-adding shareholder for companies operating in the Healthcare industries,” says Denis Ribon, ArchiMed chairman. “Management teams like to work with us because our partners and principals are specialists who can provide concrete solutions to strategic and operational challenges across healthcare sectors and geographies.”
Christophe Berthoux is joining ArchiMed as an operating partner. Previously he was chief executive of U.K.-based Synexus, a leading global provider of drug research support services and patient recruitment for clinical trials. Under the successive ownership of two private equity firms – Lyceum Capital and LDC – Berthoux oversaw the group’s expansion across the U.S., South America and Asia, generating double-digit annual revenue growth, while more than tripling international receipts. He presided over a nine-fold increase in enterprise value, leaving after the company’s 2017 sale to Carlyle-backed Pharmaceutical Product Development, one of the largest contract research organizations in healthcare. Berthoux will continue in his current non-executive chairman role at venture capital-backed Imaging Analysis Group, which uses imaging technology and artificial intelligence to streamline the development of medical treatments. He was previously U.S.-based global head of sales and marketing for Charles River Laboratories.
Berthoux graduated with an MBA from Purdue University Krannert School of Management, after earning a Doctorate in veterinary medicine and practicing as a vet.
Jean-Yves Desmottes is joining ArchiMed as an operating partner. Prior to his appointment, he was general manager of leading biology based skin care solutions group Bioderma Dermatological Laboratories. At Bioderma he successfully focused on global growth, product range expansion and margin improvement. His initiatives led to the creation of 44 affiliates throughout the world and helped increase Bioderma’s profit margin by some 50 percent, while annual sales grew more than eight-fold to €520 million. Beginning in 2014, Desmottes also served as vice-president in charge of operations at Bioderma’s parent, NAOS Group, whose other skin care brands, Institut Esthederm and Etat Pur, are also driven by biologically innovative products. Desmottes career began at Price Waterhouse Coopers, where he advised on mergers, acquisitions and restructurings in the healthcare sector.
After qualifying as a pharmacist, Desmottes earned a Masters in Marketing and Management from ESSEC in Paris.
Mario Philips, who is joining ArchiMed as a strategic partner, is the non-executive chairman of ArchiMed portfolio company Clean Biologics, a specialist in safety testing for biopharmaceuticals. In March he became chief executive of PolyneuroS, a developer of kits for the diagnosis and follow-up treatment of neurodegenerative conditions like Parkinson’s disease and Lou Gehrig’s disease. As a strategic partner at ArchiMed, he will continue in his positions at both PolyneuroS and Clean Biologics. Previously, Philips served as vice president and general manager of Pall Biotech, a unit of NYSE-listed Danaher Corporation, where he led the rapid expansion of the group’s core bioprocessing capabilities. Bioprocessing uses living cells or their components in the manufacture of drugs.
Philips graduated from Groep T – Internationale Hogeschool Leuven with a degree in Marketing, after earning a degree in Biochemistry Engineering from CTL in Gent (now Hogeschool Gent).
About ArchiMed – www.archimed-group.eu – ArchiMed is an independent investment firm specialized in the Healthcare industries. It is a strategic and financial partner to European and North American companies operating in the Biopharma, Medtech, Diagnostics, Life Sciences, Healthcare IT, Consumer Health, Public Safety and Care Services sectors. ArchiMed’s international team combines investment, medical, technological and operational experience. It works alongside management teams to accelerate their business growth through internationalization, product and service range expansion as well as capacity extension, both organically and through acquisitions. Over the last 20 years, ArchiMed’s leadership team directly managed and invested in over 40 small, medium and large-size healthcare companies throughout the world, with a combined value above five billion euros. ArchiMed’s investment capacity currently exceeds one billion euros and is potentially twice this amount when including its strategic investment partners.
David Lanchner, firstname.lastname@example.org, +33 6 33 43 5076
Stéphanie du Ché, email@example.com, +33 6 16 36 11 08